Customer Demand & Design
We begin with an in-depth consultation to understand your research objectives, then collaboratively design a customized mRNA vaccine discovery program.
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.
At Creative Biolabs, we harness the transformative power of messenger RNA (mRNA) technology for advanced anti-Monkeypox drug discovery. Leveraging our deep expertise and cutting-edge platforms, we provide comprehensive solutions and professional support, empowering clients to accelerate the development of highly effective and safe mRNA vaccine candidates against this critical pathogen.
Monkeypox virus (MPXV), a member of the orthopoxvirus family, causes a rare but potentially severe zoonotic disease. Infection typically occurs through contact with infected animals, humans, or contaminated materials. The virus replicates in the host, leading to characteristic skin lesions, fever, and other systemic symptoms.
Messenger RNA (mRNA) vaccines represent a groundbreaking approach in modern vaccinology. These innovative vaccines deliver genetic instructions to host cells, enabling them to produce specific viral antigens. This process subsequently triggers a robust and targeted immune response. To optimize their performance against pathogens like Monkeypox, mRNA vaccines often undergo modifications such as nucleoside alterations and sequence engineering, which significantly enhance their stability and translational efficiency within the body. Monkeypox mRNA vaccines offer several compelling advantages:
Fig.1 Immune response activation by an mRNA vaccine.1
Creative Biolabs offers end-to-end mRNA vaccine-based anti-Monkeypox drug discovery solutions, from initial antigen identification to comprehensive preclinical validation. Our integrated approach combines advanced bioinformatics with state-of-the-art experimental platforms, ensuring precision and efficiency in every stage of your project.
We perform exhaustive screening of MPXV surface proteins from both extracellular enveloped viruses (EVs) and intracellular mature viruses (MVs) to identify critical neutralizing antigens. Our expertise extends to optimizing antigen combinations to enhance the diversity and potency of neutralizing antibody responses, a key factor in robust immune protection.
Beyond humoral responses, we specialize in designing mRNA constructs, such as MPX-EPs, that specifically activate potent cellular immunity. This involves T-cell epitope enrichment strategies and optimizing mRNA sequences for robust cytotoxic T-lymphocyte (CTL) responses.
Our team develops tailored lipid nanoparticle (LNP) formulations, crucial for efficient and safe mRNA delivery. We conduct thorough characterization to ensure optimal stability, bioavailability, and cellular uptake.
We utilize a range of in vitro assays and relevant animal models, including humanized transgenic mice, to rigorously evaluate antibody titers, T-cell responses, and protective efficacy against MPXV challenge, ensuring robust data for preclinical advancement.
We begin with an in-depth consultation to understand your research objectives, then collaboratively design a customized mRNA vaccine discovery program.
Upon mutual agreement, a clear contract outlining deliverables, timelines, and responsibilities formalizes our transparent partnership and initiates the project.
Our expert scientists meticulously execute experiments using cutting-edge technologies for mRNA synthesis, LNP formulation, and immunological assessments, adhering to the highest quality standards.
All experimental data undergoes rigorous analysis by our experienced team, generating comprehensive, professional reports with clear interpretations and actionable insights.
Final results, including purified mRNA constructs, characterized LNPs, and detailed immunogenicity data, are delivered promptly. We also offer ongoing consultation and technical support.
Click the button to contact us for service details and a custom quote.
The versatility of mRNA technology enables its application across various aspects of Monkeypox countermeasures. Beyond traditional prophylactic vaccines, mRNA can be engineered to deliver therapeutic agents, such as instructions for in vivo production of neutralizing antibodies, offering immediate passive immunity or treatment for infected individuals. Furthermore, mRNA can be designed to express antiviral proteins or small interfering RNAs that directly interfere with viral replication, providing highly specific antiviral effects. The ability to precisely modulate host immune responses through mRNA delivery also opens avenues for enhancing innate or adaptive immunity against the virus, or mitigating infection-induced inflammation. This broad applicability positions mRNA as a pivotal tool for both preventive and therapeutic strategies against MPXV.
Rapid Development Cycle
Our agile mRNA platform significantly accelerates the timeline from target identification to preclinical candidate readiness.
Dual Immune Activation
We specialize in designing vaccines that co-activate both potent humoral and cellular immune responses for comprehensive protection.
Customized Antigen Design
Leveraging advanced bioinformatics, we identify and optimize diverse MPXV antigens, including those targeting T-cell epitopes.
Robust Preclinical Validation
Our comprehensive in vitro and in vivo testing ensures rigorous evaluation of vaccine immunogenicity and efficacy.
Integrated Expert Support
Benefit from our end-to-end service, from project design and execution to data analysis and regulatory guidance.
We conduct systematic screenings to identify crucial surface proteins from both extracellular enveloped viruses (EVs) and intracellular mature viruses (MVs). Our approach often includes well-studied antigens like A35R, B21R, M1R, and L1R, alongside novel T-cell epitope-rich regions for comprehensive immune activation.
Our team specializes in developing and optimizing lipid nanoparticle (LNP) formulations. These advanced delivery systems are meticulously characterized for their physicochemical properties, ensuring efficient encapsulation, stability, and targeted delivery of the mRNA to host cells.
Absolutely. Our core strategy focuses on designing mRNA constructs that co-activate both robust neutralizing antibody responses (humoral immunity) and potent T-cell mediated immunity (cellular immunity), which is crucial for comprehensive and long-lasting protection against viral infections.
Our unique strength lies in emphasizing the diversity of neutralizing antibodies and the synergistic co-activation of humoral and cellular immune responses. This goes beyond simply increasing antibody titers, aiming for a more complete and durable protective profile.
Indeed. Our capabilities extend to exploring mRNA as a therapeutic modality. This includes designing mRNA to express in vivo-produced neutralizing antibodies, antiviral proteins, or immunomodulatory factors to directly combat MPXV infection.
We adhere to stringent quality control protocols at every stage. This includes high-fidelity, GMP-grade mRNA synthesis, thorough characterization of LNP formulations for size, polydispersity, and encapsulation efficiency, and rigorous endotoxin testing.
Creative Biolabs is committed to long-term partnerships. We provide comprehensive final reports and offer ongoing consultation and technical support. Our team remains available to address any questions or provide further guidance as your project progresses.
Creative Biolabs is very proud to provide comprehensive mRNA vaccine-based anti-monkeypox drug discovery solutions to discover effective mRNA vaccines against monkeypox with low toxicity, few side effects, and high stability. We provide anti-monkeypox products and services, including but not limited to high-throughput screening, artificial intelligence, in vitro and in vivo platforms, and monkeypox detection services. Our dedicated team helps you design customized mRNA vaccines against the monkeypox virus for your specific application and assists you in solving your expertise questions. For more detailed information about mRNA vaccine-based anti-monkeypox drug discovery solutions, please don't hesitate to contact us.
Reference
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.